Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
smmt · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Summit Therapeutics Inc. (SMMT) measures how much investors pay for each dollar of the company's trailing earnings. SMMT's current PE ratio of N/A is calculated by dividing its stock price of $14.41 by its TTM earnings per share of -$1.36.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Summit Therapeutics Inc.You SMMT | $11.2B | N/A | — | -$1.36 |
 Ascendis Pharma A/S ASND | $12.8B | N/A | — | -$3.61 |
 BridgeBio Pharma, Inc. BBIO | $13.2B | N/A | — | -$3.70 |
 Exact Sciences Corporation EXAS | $20.0B | N/A | — | -$1.10 |
 Ionis Pharmaceuticals, Inc. IONS | $12.2B | N/A | — | -$2.38 |
 Moderna, Inc. MRNA | $18.8B | N/A | — | -$7.25 |
 Atrium Therapeutics, Inc. RNA | $202M | N/A | — | -$4.48 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.44 | — | |
2024-12-31 FY2024 | — | $-0.25 | — | |
2023-12-31 FY2023 | — | $-0.78 | — | |
2022-12-31 FY2022 | — | $-0.34 | — | |
2021-12-31 FY2021 | — | $-0.71 | — | |
2020-12-31 FY2020 | — | $-0.56 | — | |
2019-12-31 FY2019 | — | $-0.73 | — | |
2019-01-31 FY2019 | 8.04x | $0.13 | — | |
2018-01-31 FY2018 | — | $-0.31 | — | |
2017-01-31 FY2017 | — | $-0.35 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Summit Therapeutics Inc. (SMMT) measures how much investors pay for each dollar of the company's trailing earnings. SMMT's current PE ratio of N/A is calculated by dividing its stock price of $14.41 by its TTM earnings per share of -$1.36.
Frequently asked questions
SMMT pe ratio · 6 questionsSMMT's current PE ratio is N/A as of 2026-06-08, based on a stock price of $14.41 and TTM EPS of -$1.36. Data sourced from Financial Modeling Prep via SMMT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Summit Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08